A rapid, sensitive, and specific immunochroma tographic lateral flow assay for anthrax protective antigen immunity status: development and evaluation.
Sammons-DL; Biaqini-RE; Smith-JP; MacKenzie-BA; Striley-CAF; Robertson-SR; Snawder-JE
2005 Toxicology and Risk Assessment Conference, April 25-28, 2005, Holiday Inn Conference Center, Fairborn, Ohio, 2005 Apr; :22
Evidence from animals suggests that anti-protective antigen (PA) IgG from vaccination with Anthrax Vaccine Adsorbed (AVA) is protective against B. anthracis infection. Measurement of anti-PA IgG in human sera can be performed using either Enzyme-Linked Immunosorbent Assay (ELISA) or Fluorescent Covalent Microsphere Immunoassay (FCMIA, Clin Lab Diagnostic Immunol 11 :50-55, 2004). Both these methods are laboratory based. We describe the development of a rapid lateral flow immunochromatograhic assay (LFIA) test kit for the measurement of anti-PA IgG in serum or whole blood (50 ul sample) using colloidal gold nanoparticles as the detection reagent and an internal control. Using sera from 19 AVA vaccinees (anti-PA IgG range, 2.4 - 267 ug/ml), 10 controls and PA-supplemented whole blood, we demonstrated the LFIA had a sensitivity of -2 ug/ml anti-PA IgG in sera and -14 ug/ml anti-PA IgG in whole blood. Pre-adsorption of sera with PA yielded negative anti-PA LFIAs. Internal controls were positive for all tests. The diagnostic sensitivity and specificity of the assay (for human sera) were 100% using FCMIA anti-PA IgG as standard. This kit has utility for determining the immune status of individuals (military personnel, decontamination workers) vaccinated with AVA or possibly exposed to sub-clinical levels of B. anthracis.
Toxicology; Risk-analysis; Biological-warfare-agents; Biological-weapons; Decontamination; Nanotechnology
2005 Toxicology and Risk Assessment Conference, Fairborn, Ohio